期刊文献+

EGFR突变与非小细胞肺癌的个体化治疗 被引量:6

下载PDF
导出
摘要 表皮生长因子受体(epidermal growth factor receptor,EGFR)是一种蛋白酪氨酸激酶受体,在非小细胞肺癌(Non—small cell lung cancer,NSCLC)中常常过表达,并在肿瘤细胞增殖、侵袭、转移和抑制肿瘤细胞凋亡方面起到重要作用,成为治疗的重要靶点。尽管EGFR突变类型有20余种,但临床意义明确的突变位点却很少,如外显子18的G719A突变、外显子19的缺失突变和外显子21的L858R突变,其中外显子19的缺失突变最常见,不同的突变类型与临床靶向治疗的疗效及预后密切相关。在NSCLC临床治疗过程中,EGFR突变型患者对表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor—tyrosine kinase inhibitgrs,EGFR—TKI)的一线治疗和二线治疗都有显著的疗效,明显优于EGFR野生型患者,所以针对患者EGFR不同表型进行的个体化治疗尤其重要。
出处 《实用肿瘤学杂志》 CAS 2011年第1期79-82,共4页 Practical Oncology Journal
  • 相关文献

参考文献22

  • 1赵元华,周晓艺,何晓荣,徐娇珍,皮正超.同期化放疗治疗局部晚期NSCLC的临床研究[J].实用肿瘤学杂志,2008,22(1):38-40. 被引量:6
  • 2Wu M,Zhao J, Song SW, et al. EGFR mutations are associ- ated with prognosis but not with the response to first -linechemotherapy in the Chinese patients with advanced non - small cell lung cancer [ J ]. Lung Cancer, 2010,67 ( 3 ) : 343 - 347.
  • 3Kitamura A, Hosoda W, Sasaki E, et al. Immunohistochemi- cal detection of EGFR mutation using mutation - specific antibodies in lung cancer [ J ]. Clin Cancer Res, 2010, 16 ( 13 ) :3349 - 3355.
  • 4刘磊,白玉贤.EGFR靶向药物治疗胃肠道肿瘤的新进展[J].实用肿瘤学杂志,2008,22(4):382-384. 被引量:5
  • 5Wang Z, Wu YL, Zhang GC, et al. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients[ J]. Onkol- ogie ,2008,31 (4) : 174 - 178.
  • 6Choi Y J, Rho JK, Jeon BS, et al. Combined inhibition of IG- FR enhances the effects of gefitinib in H1650 :a lung cancer cell line with EGFR mutation and primary resistance to EG- FR - TK inhibitors [ J ]. Cancer Chemother Pharmacol, 2010,66(2) :381 -388.
  • 7Takeda M, Okamoto I, Fujita Y, et al. De novo resistance t1 epidermal growth factor receptor - tyrosine kinase inhibitors in EGFR mutation - positive patients with non - small cell lung cancer[J]. J Thorac Oncol,2010,5(3):399 -400.
  • 8Douillard JY, Shepherd FA, Hirsh V, et al. Molecular pre- dictors of outcome with gefitinib and docetaxel in previously treated non - small - cell lung cancer: data from the ran- domized phase III INTEREST trial[J]. J Clin Oncol,2010, 28(5) :744 -752.
  • 9Hsieh MH, Fang YF, Chang WC, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non - small cell lung cancer [ J ]. Lung Cancer, 2006, 53(3) :311 -322.
  • 10Wu JY, Yu C J, Shih JY, et al. Influence of first - line chemotherapy and EGFR mutations on second- line ge- fitinib in advanced non -small cell lung cancer[ J ]. Lung Cancer,2010,67 ( 3 ) : 348 - 354.

二级参考文献30

  • 1李中信,于跃明.中低位进展期直肠癌治疗现状及发展趋势[J].实用肿瘤杂志,2007,22(3):203-205. 被引量:2
  • 2胡雪君,宋娜,刘云鹏,马艳菊,郝艳艳,康健.EGFR、VEGF和COX-2在非小细胞肺癌中的表达和意义[J].实用肿瘤杂志,2007,22(3):209-213. 被引量:19
  • 3Mountain CF. Revisions in international system for staging lung cancer[J]. Chest, 1997;111(6) :1710-1717
  • 4Furuse K, Fukuoka M, Kawahara M, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage Ⅲ non- small-cell lung cancer[J]. J Clin Oncol, 1999;17(9) : 2692-2699
  • 5Reboul F, Brewer Y, Vincent P, et al. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage Ⅲ nonsmall sell lung cancer: a phrase Ⅱ study[ J]. Int J Radiat Oncol Biol Phys, 1996; 35(2) : 343-350
  • 6Akerley W, Hemdon JE Jr, Lyss AP, et al. Induction paclitaxel/ earboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited access study- CALGB 9534 [ J ]. Clin Lung Cancer, 2005 ;7 ( 1 ) : 47-53
  • 7Robert S, Pritchard EL, Stephen P, et al. Chemotherapy plus Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer: a Meta-Analysis[ J]. Annal Int Med, 2005 ;129(3) : 723-729
  • 8Furuse K,Fukuoka M,Kuba M,et al. Randomized study of vinorelbine(VRB) versus vindesine (VDS) in previously untreated stage Ⅲb-Ⅳ non-small-cell lung cancer(NSCLC) [ J ]. Ann Oncol. 1996; 7(8) :815
  • 9Katayama H, Ucoka H, Kiura H, et al. Preoprative concurrent chemotherapy with cisplatin and docctaxel in patients with locally advanced non-small-cell lung cancer [J ]. Briti Cancer, 2004;90 ( 5 ) : 979-984
  • 10Fisher MD, DOrazio A. Concurrent chemoradiotherapy followed by consolidation docetaxel in stage ⅢB non small-cell lung cancer ( SWOG 9504) [ J]. Clin Lung Cancer. 2000 ; 2( 1 ) : 25-26

共引文献9

同被引文献85

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部